These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20811684)

  • 1. VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cells.
    Li Y; Yang X; Su LJ; Flaig TW
    Oncol Rep; 2010 Oct; 24(4):1019-28. PubMed ID: 20811684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner.
    Flaig TW; Su LJ; McCoach C; Li Y; Raben D; Varella-Garcia M; Bemis LT
    BJU Int; 2009 Jun; 103(12):1729-37. PubMed ID: 19220256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.
    Sano D; Matsumoto F; Valdecanas DR; Zhao M; Molkentine DP; Takahashi Y; Hanna EY; Papadimitrakopoulou V; Heymach J; Milas L; Myers JN
    Clin Cancer Res; 2011 Apr; 17(7):1815-27. PubMed ID: 21350000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
    Lyros O; Mueller A; Heidel F; Schimanski CC; Gockel I; Galle PR; Lang H; Moehler M
    Int J Cancer; 2010 Sep; 127(5):1197-208. PubMed ID: 20039326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial mesenchymal transition status is associated with anti-cancer responses towards receptor tyrosine-kinase inhibition by dovitinib in human bladder cancer cells.
    Hänze J; Henrici M; Hegele A; Hofmann R; Olbert PJ
    BMC Cancer; 2013 Dec; 13():589. PubMed ID: 24325461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of IκBα in bladder cancer cell lines is negatively correlated with epithelial-mesenchymal transition and cell invasion in vitro].
    Wang X; Cheng H; Chen Y; Li H; He D
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Nov; 30(11):1159-61. PubMed ID: 25374080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells.
    Bianco R; Rosa R; Damiano V; Daniele G; Gelardi T; Garofalo S; Tarallo V; De Falco S; Melisi D; Benelli R; Albini A; Ryan A; Ciardiello F; Tortora G
    Clin Cancer Res; 2008 Aug; 14(16):5069-80. PubMed ID: 18694994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual inhibition of vascular endothelial growth factor receptor and epidermal growth factor receptor is an effective chemopreventive strategy in the mouse 4-NQO model of oral carcinogenesis.
    Zhou G; Hasina R; Wroblewski K; Mankame TP; Doçi CL; Lingen MW
    Cancer Prev Res (Phila); 2010 Nov; 3(11):1493-502. PubMed ID: 20978113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNFAIP2 expression induces epithelial-to-mesenchymal transition and confers platinum resistance in urothelial cancer cells.
    Niwa N; Tanaka N; Hongo H; Miyazaki Y; Takamatsu K; Mizuno R; Kikuchi E; Mikami S; Kosaka T; Oya M
    Lab Invest; 2019 Nov; 99(11):1702-1713. PubMed ID: 31263157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incomplete epithelial-mesenchymal transition in p16-positive squamous cell carcinoma cells correlates with β-catenin expression.
    Umbreit C; Flanjak J; Weiss C; Erben P; Aderhold C; Faber A; Stern-Straeter J; Hoermann K; Schultz JD
    Anticancer Res; 2014 Dec; 34(12):7061-9. PubMed ID: 25503133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.
    Siegfried JM; Gubish CT; Rothstein ME; Henry C; Stabile LP
    J Thorac Oncol; 2012 Mar; 7(3):485-95. PubMed ID: 22258476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel role of Id-1 in regulation of epithelial-to-mesenchymal transition in bladder cancer.
    Hu H; Wang YL; Wang GW; Wong YC; Wang XF; Wang Y; Xu KX
    Urol Oncol; 2013 Oct; 31(7):1242-53. PubMed ID: 22226665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.
    Brave SR; Odedra R; James NH; Smith NR; Marshall GB; Acheson KL; Baker D; Howard Z; Jackson L; Ratcliffe K; Wainwright A; Lovick SC; Hickinson DM; Wilkinson RW; Barry ST; Speake G; Ryan AJ
    Int J Oncol; 2011 Jul; 39(1):271-8. PubMed ID: 21537841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular correlates of gefitinib responsiveness in human bladder cancer cells.
    Shrader M; Pino MS; Brown G; Black P; Adam L; Bar-Eli M; Dinney CP; McConkey DJ
    Mol Cancer Ther; 2007 Jan; 6(1):277-85. PubMed ID: 17237287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.
    Fuchs BC; Fujii T; Dorfman JD; Goodwin JM; Zhu AX; Lanuti M; Tanabe KK
    Cancer Res; 2008 Apr; 68(7):2391-9. PubMed ID: 18381447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells.
    Yang AD; Camp ER; Fan F; Shen L; Gray MJ; Liu W; Somcio R; Bauer TW; Wu Y; Hicklin DJ; Ellis LM
    Cancer Res; 2006 Jan; 66(1):46-51. PubMed ID: 16397214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Investigation of epithelial-mesenchymal transition induced by cisplatin on human laryngeal resistant cancer cells].
    Gong XR; Yu F; Zhou YB
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Dec; 31(23):1839-1843. PubMed ID: 29798399
    [No Abstract]   [Full Text] [Related]  

  • 18. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
    Gustafson DL; Frederick B; Merz AL; Raben D
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):179-88. PubMed ID: 17393165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific N-glycan alterations are coupled in epithelial-mesenchymal transition induced by EGF in GE11 epithelial cells.
    Xu Q; Qu C; Wang W; Gu J; Du Y; Song L
    Cell Biol Int; 2017 Feb; 41(2):124-133. PubMed ID: 27888538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial-mesenchymal transition is necessary for acquired resistance to cisplatin and increases the metastatic potential of nasopharyngeal carcinoma cells.
    Zhang P; Liu H; Xia F; Zhang QW; Zhang YY; Zhao Q; Chao ZH; Jiang ZW; Jiang CC
    Int J Mol Med; 2014 Jan; 33(1):151-9. PubMed ID: 24173500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.